23 September 2022 in Hepatology Forum
Background and Aim: The aim of the present study was to examine the etiology of hepatocellular carcinoma (HCC) by underlying cause and determine the characteristics and clinical features of patients with HCC. Materials and Methods: The study comprised 1802 HCC patients diagnosed and followed up by Liver Diseases Outpatient Clinics in 14 tertiary centers in Turkey between 2001 and 2020. Results: The mean age was 62.3±10.7 years, and 78% of them were males. Of the patients, 82% had cirrhosis. Hepatitis B virus (HBV) infection was the most common etiology (54%), followed by hepatitis C virus (HCV) infection (19%) and nonalcoholic fatty liver disease (NAFLD) (10%). Of the patients, 56% had a single lesion. Macrovascular invasion and extrahepatic spread were present in 15% and 12% of the patients, respectively. The median serum alpha-fetoprotein level was 25.4 ng/mL. In total, 39% of the patients fulfilled the Milan Criteria. When we compared the characteristics of patients diagnosed before and after January 2016, the proportion of NAFLD-related HCC cases increased after 2016, from 6.6% to 13.4%. Conclusion: Chronic HBV and HCV infections remain the main causes of HCC in Turkey. The importance of NAFLD as a cause of HCC is increasing.
15 December 2020 in Turkish Journal of Gastroenterology
Background/Aims: This study aimed to evaluate the real-life efficacy and tolerability of direct-acting antiviral treatments for patients with chronic hepatitis C (CHC) with/without cirrhosis in the Turkish population. Material and Methods: A total of 4,352 patients with CHC from 36 different institutions in Turkey were enrolled. They received ledipasvir (LDV) and sofosbuvir (SOF)±ribavirin (RBV) orombitasvir/paritaprevir/ritonavir±dasabuvir (PrOD)±RBV for 12 or 24 weeks. Sustained virologic response (SVR) rates, factors affecting SVR, safety profile, and hepatocellular cancer (HCC) occurrence were analyzed. Results: SVR12 was achieved in 92.8% of the patients (4,040/4,352) according to intention-to-treat and in 98.3% of the patients (4,040/4,108) according to per-protocol analysis. The SVR12 rates were similar between the treatment regimens (97.2%–100%) and genotypes (95.6%–100%). Patients achieving SVR showed a significant decrease in the mean serum alanine transaminase (ALT) levels (50.90±54.60 U/L to 17.00±14.50 U/L) and model for end-stage liver disease (MELD) scores (7.51±4.54 to 7.32±3.40) (p<0.05). Of the patients, 2 were diagnosed with HCC during the treatment and 14 were diagnosed with HCC 37.0±16.0 weeks post-treatment. Higher initial MELD score (odds ratio [OR]: 1.92, 95% confidence interval [CI]: 1.22–2.38; p=0.023]), higher hepatitis C virus (HCV) RNA levels (OR: 1.44, 95% CI: 1.31–2.28; p=0.038), and higher serum ALT levels (OR: 1.38, 95% CI: 1.21–1.83; p=0.042) were associated with poor SVR12. The most common adverse events were fatigue (12.6%), pruritis (7.3%), increased serum ALT (4.7%) and bilirubin (3.8%) levels, and anemia (3.1%). Conclusion: LDV/SOF or PrOD±RBV were effective and tolerable treatments for patients with CHC and with or without advanced liver disease before and after liver transplantation. Although HCV eradication improves the liver function, there is a risk of developing HCC.
12 April 2025 in Family Practice
Background: Defensive medicine, characterized by the avoidance of high-risk patients or the overuse of diagnostic and therapeutic interventions due to fear of litigation or complaints, poses significant challenges in primary care. Existing scales primarily focus on hospital settings, limiting their applicability to family physicians. This study aimed to develop and validate a scale tailored to measure defensive medicine behaviors in primary care contexts. Methods: Scale development involved reviewing the literature, conducting focus group discussions with family physicians, and consulting with experts. An initial 37-item draft was pilot-tested for clarity, resulting in a refined instrument. Data were collected from family physicians in two phases: exploratory factor analysis (EFA) with 252 participants and confirmatory factor analysis with 266 participants. Criterion validity was assessed by correlating the new scale with a previously validated defensive medicine scale. Reliability was evaluated using Cronbach’s alpha and McDonald’s omega. Results: EFA supported a five-factor structure: referral, complaint, e-report, verbal/physical violence, and interventional procedure dimensions. After item removal, the final 21-item scale demonstrated acceptable goodness-of-fit indices (χ²/df = 2.43, root mean square error of approximation (RMSEA) = 0.07, comparative-fit index (CFI) = 0.93). Criterion validity was evidenced by a moderate positive correlation (r = 0.350, P < .01) with an existing scale. Internal consistency was high, with both Cronbach’s alpha and McDonald’s omega at 0.92 for the total scale. Conclusions: The Primary Care Defensive Medicine Practices Scale is a valid and reliable instrument specifically tailored for primary care settings. It offers a more nuanced understanding of defensive behaviors, guiding targeted interventions to enhance care quality, patient safety, and resource utilization.